Sodium-glucose cotransporter-2 (SGLT2) inhibitors (canagliflozin, dapagliflozin, and empagliflozin) can increase risk of urinary tract infections, fungal infections, and hypovolemia with orthostatic hypotension; they should be avoided in patients with impaired renal function.